CDEK
← All organizations

Leading BioSciences, Inc

For profitWebsite ↗

Also known as: Inflammagen | Inflammagen/Leading Ventures | Leading BioSciences, Inc | Shanxi Zhendong Leading Biotechnology Co., Ltd.

Phase 1Phase 2Phase 3Phase 4

First clinical trial

Jun 1, 2012

Last known activity

Jun 30, 2020

Acquired by Seneca Biopharma, Inc. → Leading BioSciences, Inc → Seneca Biopharma, Inc. → Leading BioSciences, Inc → Seneca Biopharma, Inc. → Leading BioSciences, Inc → Seneca Biopharma, Inc. → Leading BioSciences, Inc → Seneca Biopharma, Inc. → Leading BioSciences, Inc → Seneca Biopharma, Inc. → Leading BioSciences, Inc → Seneca Biopharma, Inc. → Leading BioSciences, Inc → Seneca Biopharma, Inc. → Leading BioSciences, Inc → Seneca Biopharma, Inc. → Leading BioSciences, Inc → Seneca Biopharma, Inc. → Leading BioSciences, Inc → Seneca Biopharma, Inc. → Leading BioSciences, Inc → Seneca Biopharma, Inc. → Leading BioSciences, Inc → Seneca Biopharma, Inc. on Apr 26, 2021

Timeline

2000s

  1. Jun 1, 2005

    Leading BioSciences, Inc— Founded

2020s

  1. Apr 6, 2021

    Seneca Biopharma, Inc.— Acquired

  2. Apr 26, 2021

    Seneca Biopharma, Inc.— Acquired By

  3. Apr 26, 2021

    Seneca Biopharma, Inc.— Now

Drugs by trial phase (6 distinct, 10 trials)

Phase 2 (0 own, 2 via acquisition)

Phase 1 (0 own, 4 via acquisition)

Indications

Studied for

Subsidiaries (1 direct, 25 total across the full acquisition tree)

Recent trials (6)

Details

Founded
Solana Beach, CA, US Jun 1, 2005
Last known activity
Jun 30, 2020